Search

Search Constraints

You searched for: Author/Creator Martinez, Felipe A.

Search Results

11. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. (27th August 2022)

12. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Issue 2 (14th January 2020)

13. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. (22nd November 2021)

14. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. (December 2021)

15. Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF. (15th June 2020)

16. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. (29th July 2021)

17. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Issue 4 (26th January 2021)

18. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Issue 6 (20th April 2022)

19. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Issue 13 (16th August 2022)

20. Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF. (22nd August 2022)